nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—TOP2A—Epirubicin—bone cancer	0.378	0.542	CbGbCtD
Amsacrine—TOP2A—Doxorubicin—bone cancer	0.201	0.288	CbGbCtD
Amsacrine—ABCB1—Cisplatin—bone cancer	0.0401	0.0575	CbGbCtD
Amsacrine—ABCB1—Doxorubicin—bone cancer	0.0269	0.0385	CbGbCtD
Amsacrine—ABCB1—Methotrexate—bone cancer	0.026	0.0373	CbGbCtD
Amsacrine—CYP2D6—Doxorubicin—bone cancer	0.0253	0.0363	CbGbCtD
Amsacrine—TOP2A—Gastric Cancer Network 1—C21orf33—bone cancer	0.00928	0.119	CbGpPWpGaD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—T—bone cancer	0.00536	0.0689	CbGpPWpGaD
Amsacrine—KCNH2—Hematopoietic Stem Cell Differentiation—FLI1—bone cancer	0.00525	0.0674	CbGpPWpGaD
Amsacrine—NCOA3—Idarubicin—Epirubicin—bone cancer	0.0031	0.368	CbGdCrCtD
Amsacrine—NCOA3—Idarubicin—Doxorubicin—bone cancer	0.00287	0.34	CbGdCrCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—FEV—bone cancer	0.00233	0.03	CbGpPWpGaD
Amsacrine—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00169	0.0217	CbGpPWpGaD
Amsacrine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00159	0.0205	CbGpPWpGaD
Amsacrine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00159	0.0204	CbGpPWpGaD
Amsacrine—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00159	0.0204	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00158	0.0203	CbGpPWpGaD
Amsacrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL3—bone cancer	0.00137	0.0176	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00127	0.0163	CbGpPWpGaD
Amsacrine—NCOA3—FOXA1 transcription factor network—JUN—bone cancer	0.0012	0.0154	CbGpPWpGaD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.00119	0.0153	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00115	0.0147	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.0011	0.0142	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—ATF1—bone cancer	0.00108	0.0139	CbGpPWpGaD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	0.00104	0.0134	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000956	0.0123	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000934	0.012	CbGpPWpGaD
Amsacrine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000926	0.0119	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—RB1—bone cancer	0.00092	0.0118	CbGpPWpGaD
Amsacrine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000916	0.0118	CbGpPWpGaD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00091	0.0117	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000899	0.0115	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000887	0.0114	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—MDM2—bone cancer	0.000784	0.0101	CbGpPWpGaD
Amsacrine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000766	0.00984	CbGpPWpGaD
Amsacrine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000737	0.00947	CbGpPWpGaD
Amsacrine—Creatinine increased—Epirubicin—bone cancer	0.000735	0.0034	CcSEcCtD
Amsacrine—Inflammation—Epirubicin—bone cancer	0.000722	0.00333	CcSEcCtD
Amsacrine—Hepatobiliary disease—Cisplatin—bone cancer	0.000721	0.00333	CcSEcCtD
Amsacrine—Blood uric acid increased—Epirubicin—bone cancer	0.000713	0.00329	CcSEcCtD
Amsacrine—Musculoskeletal pain—Epirubicin—bone cancer	0.000709	0.00327	CcSEcCtD
Amsacrine—Aplastic anaemia—Methotrexate—bone cancer	0.000702	0.00324	CcSEcCtD
Amsacrine—Phosphatase alkaline increased—Epirubicin—bone cancer	0.0007	0.00323	CcSEcCtD
Amsacrine—Hyperuricaemia—Doxorubicin—bone cancer	0.000698	0.00323	CcSEcCtD
Amsacrine—Bradycardia—Cisplatin—bone cancer	0.000697	0.00322	CcSEcCtD
Amsacrine—Injection site reaction—Epirubicin—bone cancer	0.000696	0.00321	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000693	0.0089	CbGpPWpGaD
Amsacrine—Blood bilirubin increased—Doxorubicin—bone cancer	0.000685	0.00316	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000683	0.00878	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—JUN—bone cancer	0.000682	0.00876	CbGpPWpGaD
Amsacrine—Creatinine increased—Doxorubicin—bone cancer	0.000681	0.00314	CcSEcCtD
Amsacrine—Urinary tract disorder—Cisplatin—bone cancer	0.000676	0.00312	CcSEcCtD
Amsacrine—Connective tissue disorder—Cisplatin—bone cancer	0.000673	0.00311	CcSEcCtD
Amsacrine—Urethral disorder—Cisplatin—bone cancer	0.000671	0.0031	CcSEcCtD
Amsacrine—Inflammation—Doxorubicin—bone cancer	0.000668	0.00308	CcSEcCtD
Amsacrine—Blood urea increased—Epirubicin—bone cancer	0.000661	0.00305	CcSEcCtD
Amsacrine—Blood uric acid increased—Doxorubicin—bone cancer	0.00066	0.00305	CcSEcCtD
Amsacrine—Aplastic anaemia—Epirubicin—bone cancer	0.000657	0.00304	CcSEcCtD
Amsacrine—Musculoskeletal pain—Doxorubicin—bone cancer	0.000656	0.00303	CcSEcCtD
Amsacrine—Sepsis—Methotrexate—bone cancer	0.000649	0.003	CcSEcCtD
Amsacrine—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000648	0.00299	CcSEcCtD
Amsacrine—Injection site reaction—Doxorubicin—bone cancer	0.000644	0.00297	CcSEcCtD
Amsacrine—Cardiac disorder—Cisplatin—bone cancer	0.000635	0.00293	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—DHFR—bone cancer	0.000633	0.00813	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Cisplatin—bone cancer	0.000617	0.00285	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000613	0.00788	CbGpPWpGaD
Amsacrine—Arrhythmia—Cisplatin—bone cancer	0.000612	0.00282	CcSEcCtD
Amsacrine—Blood urea increased—Doxorubicin—bone cancer	0.000612	0.00282	CcSEcCtD
Amsacrine—Aplastic anaemia—Doxorubicin—bone cancer	0.000608	0.00281	CcSEcCtD
Amsacrine—Sepsis—Epirubicin—bone cancer	0.000608	0.00281	CcSEcCtD
Amsacrine—Alopecia—Cisplatin—bone cancer	0.000605	0.00279	CcSEcCtD
Amsacrine—Hepatic failure—Methotrexate—bone cancer	0.000604	0.00279	CcSEcCtD
Amsacrine—NCOA3—Metabolism—NDUFA12—bone cancer	0.000604	0.00775	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000603	0.00774	CbGpPWpGaD
Amsacrine—Malnutrition—Cisplatin—bone cancer	0.000596	0.00275	CcSEcCtD
Amsacrine—Phlebitis—Epirubicin—bone cancer	0.00059	0.00272	CcSEcCtD
Amsacrine—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000584	0.0027	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—BRAF—bone cancer	0.00058	0.00745	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000576	0.0074	CbGpPWpGaD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	0.000573	0.00736	CbGpPWpGaD
Amsacrine—Vascular purpura—Epirubicin—bone cancer	0.000568	0.00262	CcSEcCtD
Amsacrine—Hepatic failure—Epirubicin—bone cancer	0.000566	0.00261	CcSEcCtD
Amsacrine—Sepsis—Doxorubicin—bone cancer	0.000562	0.0026	CcSEcCtD
Amsacrine—Vision blurred—Cisplatin—bone cancer	0.000562	0.00259	CcSEcCtD
Amsacrine—Cardiac failure congestive—Epirubicin—bone cancer	0.00056	0.00259	CcSEcCtD
Amsacrine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000558	0.00717	CbGpPWpGaD
Amsacrine—Lethargy—Methotrexate—bone cancer	0.000554	0.00256	CcSEcCtD
Amsacrine—Anaemia—Cisplatin—bone cancer	0.000551	0.00254	CcSEcCtD
Amsacrine—TOP2A—Gastric Cancer Network 2—EGFR—bone cancer	0.000546	0.00702	CbGpPWpGaD
Amsacrine—Phlebitis—Doxorubicin—bone cancer	0.000546	0.00252	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—ZW10—bone cancer	0.000545	0.007	CbGpPWpGaD
Amsacrine—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000541	0.0025	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—EGFR—bone cancer	0.000536	0.00688	CbGpPWpGaD
Amsacrine—Leukopenia—Cisplatin—bone cancer	0.000533	0.00246	CcSEcCtD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000532	0.00683	CbGpPWpGaD
Amsacrine—Purpura—Epirubicin—bone cancer	0.000527	0.00244	CcSEcCtD
Amsacrine—Vascular purpura—Doxorubicin—bone cancer	0.000526	0.00243	CcSEcCtD
Amsacrine—Hepatic failure—Doxorubicin—bone cancer	0.000523	0.00242	CcSEcCtD
Amsacrine—Lethargy—Epirubicin—bone cancer	0.000519	0.0024	CcSEcCtD
Amsacrine—Cardiac failure congestive—Doxorubicin—bone cancer	0.000519	0.00239	CcSEcCtD
Amsacrine—Convulsion—Cisplatin—bone cancer	0.000516	0.00239	CcSEcCtD
Amsacrine—Mood swings—Methotrexate—bone cancer	0.000514	0.00238	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000514	0.0066	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000504	0.00233	CcSEcCtD
Amsacrine—Affect lability—Epirubicin—bone cancer	0.0005	0.00231	CcSEcCtD
Amsacrine—NCOA3—Metabolism—NT5C3A—bone cancer	0.0005	0.00643	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00049	0.00629	CbGpPWpGaD
Amsacrine—Purpura—Doxorubicin—bone cancer	0.000488	0.00225	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—ZW10—bone cancer	0.000487	0.00626	CbGpPWpGaD
Amsacrine—Infection—Cisplatin—bone cancer	0.000483	0.00223	CcSEcCtD
Amsacrine—Mood swings—Epirubicin—bone cancer	0.000481	0.00222	CcSEcCtD
Amsacrine—Lethargy—Doxorubicin—bone cancer	0.00048	0.00222	CcSEcCtD
Amsacrine—Thrombocytopenia—Cisplatin—bone cancer	0.000476	0.0022	CcSEcCtD
Amsacrine—Blood creatinine increased—Epirubicin—bone cancer	0.000476	0.0022	CcSEcCtD
Amsacrine—Tachycardia—Cisplatin—bone cancer	0.000475	0.00219	CcSEcCtD
Amsacrine—Skin disorder—Cisplatin—bone cancer	0.000472	0.00218	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000472	0.00607	CbGpPWpGaD
Amsacrine—Anorexia—Cisplatin—bone cancer	0.000464	0.00214	CcSEcCtD
Amsacrine—Affect lability—Doxorubicin—bone cancer	0.000463	0.00214	CcSEcCtD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—bone cancer	0.000459	0.00589	CbGpPWpGaD
Amsacrine—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000458	0.00211	CcSEcCtD
Amsacrine—Hypotension—Cisplatin—bone cancer	0.000455	0.0021	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000447	0.00574	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000446	0.00573	CbGpPWpGaD
Amsacrine—Pancytopenia—Methotrexate—bone cancer	0.000446	0.00206	CcSEcCtD
Amsacrine—Mood swings—Doxorubicin—bone cancer	0.000445	0.00206	CcSEcCtD
Amsacrine—Blood creatinine increased—Doxorubicin—bone cancer	0.000441	0.00203	CcSEcCtD
Amsacrine—Dysphagia—Epirubicin—bone cancer	0.000439	0.00203	CcSEcCtD
Amsacrine—Paraesthesia—Cisplatin—bone cancer	0.000437	0.00202	CcSEcCtD
Amsacrine—Dyspnoea—Cisplatin—bone cancer	0.000434	0.002	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—GNA11—bone cancer	0.00043	0.00552	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—EZH2—bone cancer	0.000428	0.0055	CbGpPWpGaD
Amsacrine—TOP2A—Idarubicin—Epirubicin—bone cancer	0.000425	0.0505	CbGdCrCtD
Amsacrine—TOP2A—Daunorubicin—Epirubicin—bone cancer	0.000425	0.0505	CbGdCrCtD
Amsacrine—TOP2A—Doxorubicin—Epirubicin—bone cancer	0.000425	0.0505	CbGdCrCtD
Amsacrine—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000423	0.00196	CcSEcCtD
Amsacrine—Decreased appetite—Cisplatin—bone cancer	0.000423	0.00195	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—JUN—bone cancer	0.000422	0.00542	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00042	0.00194	CcSEcCtD
Amsacrine—Infestation NOS—Methotrexate—bone cancer	0.000418	0.00193	CcSEcCtD
Amsacrine—Infestation—Methotrexate—bone cancer	0.000418	0.00193	CcSEcCtD
Amsacrine—Pancytopenia—Epirubicin—bone cancer	0.000417	0.00193	CcSEcCtD
Amsacrine—Pain—Cisplatin—bone cancer	0.000416	0.00192	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000413	0.0053	CbGpPWpGaD
Amsacrine—Renal failure—Methotrexate—bone cancer	0.000411	0.0019	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000411	0.00527	CbGpPWpGaD
Amsacrine—Stomatitis—Methotrexate—bone cancer	0.000408	0.00188	CcSEcCtD
Amsacrine—Dysphagia—Doxorubicin—bone cancer	0.000406	0.00188	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000406	0.00522	CbGpPWpGaD
Amsacrine—Feeling abnormal—Cisplatin—bone cancer	0.000401	0.00185	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000401	0.00515	CbGpPWpGaD
Amsacrine—Weight increased—Epirubicin—bone cancer	0.0004	0.00185	CcSEcCtD
Amsacrine—Haematuria—Methotrexate—bone cancer	0.000399	0.00184	CcSEcCtD
Amsacrine—Weight decreased—Epirubicin—bone cancer	0.000397	0.00184	CcSEcCtD
Amsacrine—Hepatobiliary disease—Methotrexate—bone cancer	0.000396	0.00183	CcSEcCtD
Amsacrine—TOP2A—Daunorubicin—Doxorubicin—bone cancer	0.000394	0.0468	CbGdCrCtD
Amsacrine—TOP2A—Epirubicin—Doxorubicin—bone cancer	0.000394	0.0468	CbGdCrCtD
Amsacrine—TOP2A—Idarubicin—Doxorubicin—bone cancer	0.000394	0.0468	CbGdCrCtD
Amsacrine—Infestation NOS—Epirubicin—bone cancer	0.000392	0.00181	CcSEcCtD
Amsacrine—Infestation—Epirubicin—bone cancer	0.000392	0.00181	CcSEcCtD
Amsacrine—Agranulocytosis—Methotrexate—bone cancer	0.000391	0.0018	CcSEcCtD
Amsacrine—Pancytopenia—Doxorubicin—bone cancer	0.000386	0.00178	CcSEcCtD
Amsacrine—Renal failure—Epirubicin—bone cancer	0.000385	0.00178	CcSEcCtD
Amsacrine—Body temperature increased—Cisplatin—bone cancer	0.000385	0.00178	CcSEcCtD
Amsacrine—Stomatitis—Epirubicin—bone cancer	0.000382	0.00176	CcSEcCtD
Amsacrine—Jaundice—Epirubicin—bone cancer	0.000382	0.00176	CcSEcCtD
Amsacrine—Haemoglobin—Methotrexate—bone cancer	0.000378	0.00174	CcSEcCtD
Amsacrine—Hepatitis—Methotrexate—bone cancer	0.000376	0.00174	CcSEcCtD
Amsacrine—Haemorrhage—Methotrexate—bone cancer	0.000376	0.00174	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—RFC1—bone cancer	0.000374	0.00481	CbGpPWpGaD
Amsacrine—Haematuria—Epirubicin—bone cancer	0.000373	0.00172	CcSEcCtD
Amsacrine—Urinary tract disorder—Methotrexate—bone cancer	0.000371	0.00171	CcSEcCtD
Amsacrine—Hepatobiliary disease—Epirubicin—bone cancer	0.00037	0.00171	CcSEcCtD
Amsacrine—Weight increased—Doxorubicin—bone cancer	0.00037	0.00171	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—TUBB4B—bone cancer	0.000369	0.00474	CbGpPWpGaD
Amsacrine—Urethral disorder—Methotrexate—bone cancer	0.000368	0.0017	CcSEcCtD
Amsacrine—Weight decreased—Doxorubicin—bone cancer	0.000368	0.0017	CcSEcCtD
Amsacrine—Agranulocytosis—Epirubicin—bone cancer	0.000365	0.00169	CcSEcCtD
Amsacrine—Infestation—Doxorubicin—bone cancer	0.000362	0.00167	CcSEcCtD
Amsacrine—Infestation NOS—Doxorubicin—bone cancer	0.000362	0.00167	CcSEcCtD
Amsacrine—Hypersensitivity—Cisplatin—bone cancer	0.000358	0.00166	CcSEcCtD
Amsacrine—Bradycardia—Epirubicin—bone cancer	0.000358	0.00165	CcSEcCtD
Amsacrine—Renal failure—Doxorubicin—bone cancer	0.000356	0.00165	CcSEcCtD
Amsacrine—Haemoglobin—Epirubicin—bone cancer	0.000353	0.00163	CcSEcCtD
Amsacrine—Stomatitis—Doxorubicin—bone cancer	0.000353	0.00163	CcSEcCtD
Amsacrine—Jaundice—Doxorubicin—bone cancer	0.000353	0.00163	CcSEcCtD
Amsacrine—Haemorrhage—Epirubicin—bone cancer	0.000352	0.00162	CcSEcCtD
Amsacrine—Hepatitis—Epirubicin—bone cancer	0.000352	0.00162	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000351	0.00451	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.00035	0.0045	CbGpPWpGaD
Amsacrine—Hypoaesthesia—Epirubicin—bone cancer	0.00035	0.00162	CcSEcCtD
Amsacrine—Asthenia—Cisplatin—bone cancer	0.000349	0.00161	CcSEcCtD
Amsacrine—Cardiac disorder—Methotrexate—bone cancer	0.000349	0.00161	CcSEcCtD
Amsacrine—Urinary tract disorder—Epirubicin—bone cancer	0.000347	0.0016	CcSEcCtD
Amsacrine—Haematuria—Doxorubicin—bone cancer	0.000346	0.0016	CcSEcCtD
Amsacrine—Connective tissue disorder—Epirubicin—bone cancer	0.000345	0.0016	CcSEcCtD
Amsacrine—Urethral disorder—Epirubicin—bone cancer	0.000345	0.00159	CcSEcCtD
Amsacrine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000343	0.00158	CcSEcCtD
Amsacrine—Angiopathy—Methotrexate—bone cancer	0.000341	0.00157	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000339	0.00436	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Methotrexate—bone cancer	0.000339	0.00156	CcSEcCtD
Amsacrine—Agranulocytosis—Doxorubicin—bone cancer	0.000338	0.00156	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—RFC1—bone cancer	0.000335	0.0043	CbGpPWpGaD
Amsacrine—Diarrhoea—Cisplatin—bone cancer	0.000333	0.00154	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000332	0.00427	CbGpPWpGaD
Amsacrine—Alopecia—Methotrexate—bone cancer	0.000332	0.00153	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—EGFR—bone cancer	0.000332	0.00426	CbGpPWpGaD
Amsacrine—Bradycardia—Doxorubicin—bone cancer	0.000331	0.00153	CcSEcCtD
Amsacrine—Mental disorder—Methotrexate—bone cancer	0.000329	0.00152	CcSEcCtD
Amsacrine—Malnutrition—Methotrexate—bone cancer	0.000327	0.00151	CcSEcCtD
Amsacrine—Haemoglobin—Doxorubicin—bone cancer	0.000327	0.00151	CcSEcCtD
Amsacrine—Cardiac disorder—Epirubicin—bone cancer	0.000326	0.00151	CcSEcCtD
Amsacrine—Haemorrhage—Doxorubicin—bone cancer	0.000325	0.0015	CcSEcCtD
Amsacrine—Hepatitis—Doxorubicin—bone cancer	0.000325	0.0015	CcSEcCtD
Amsacrine—Hypoaesthesia—Doxorubicin—bone cancer	0.000324	0.0015	CcSEcCtD
Amsacrine—Urinary tract disorder—Doxorubicin—bone cancer	0.000321	0.00148	CcSEcCtD
Amsacrine—Connective tissue disorder—Doxorubicin—bone cancer	0.00032	0.00148	CcSEcCtD
Amsacrine—Angiopathy—Epirubicin—bone cancer	0.000319	0.00147	CcSEcCtD
Amsacrine—Urethral disorder—Doxorubicin—bone cancer	0.000319	0.00147	CcSEcCtD
Amsacrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000318	0.00409	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Epirubicin—bone cancer	0.000317	0.00146	CcSEcCtD
Amsacrine—Arrhythmia—Epirubicin—bone cancer	0.000314	0.00145	CcSEcCtD
Amsacrine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000314	0.00403	CbGpPWpGaD
Amsacrine—Alopecia—Epirubicin—bone cancer	0.000311	0.00143	CcSEcCtD
Amsacrine—Vomiting—Cisplatin—bone cancer	0.000309	0.00143	CcSEcCtD
Amsacrine—Vision blurred—Methotrexate—bone cancer	0.000308	0.00142	CcSEcCtD
Amsacrine—Mental disorder—Epirubicin—bone cancer	0.000308	0.00142	CcSEcCtD
Amsacrine—Rash—Cisplatin—bone cancer	0.000307	0.00142	CcSEcCtD
Amsacrine—Dermatitis—Cisplatin—bone cancer	0.000306	0.00142	CcSEcCtD
Amsacrine—Malnutrition—Epirubicin—bone cancer	0.000306	0.00141	CcSEcCtD
Amsacrine—Anaemia—Methotrexate—bone cancer	0.000302	0.0014	CcSEcCtD
Amsacrine—Cardiac disorder—Doxorubicin—bone cancer	0.000302	0.00139	CcSEcCtD
Amsacrine—Angiopathy—Doxorubicin—bone cancer	0.000295	0.00136	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000295	0.00379	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Doxorubicin—bone cancer	0.000293	0.00135	CcSEcCtD
Amsacrine—Leukopenia—Methotrexate—bone cancer	0.000293	0.00135	CcSEcCtD
Amsacrine—Arrhythmia—Doxorubicin—bone cancer	0.000291	0.00134	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—RB1—bone cancer	0.000289	0.00371	CbGpPWpGaD
Amsacrine—Nausea—Cisplatin—bone cancer	0.000289	0.00133	CcSEcCtD
Amsacrine—Vision blurred—Epirubicin—bone cancer	0.000288	0.00133	CcSEcCtD
Amsacrine—Alopecia—Doxorubicin—bone cancer	0.000287	0.00133	CcSEcCtD
Amsacrine—Mental disorder—Doxorubicin—bone cancer	0.000285	0.00132	CcSEcCtD
Amsacrine—Convulsion—Methotrexate—bone cancer	0.000283	0.00131	CcSEcCtD
Amsacrine—Malnutrition—Doxorubicin—bone cancer	0.000283	0.00131	CcSEcCtD
Amsacrine—Anaemia—Epirubicin—bone cancer	0.000283	0.00131	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000277	0.00128	CcSEcCtD
Amsacrine—Leukopenia—Epirubicin—bone cancer	0.000274	0.00127	CcSEcCtD
Amsacrine—Confusional state—Methotrexate—bone cancer	0.000269	0.00124	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—CDK4—bone cancer	0.000268	0.00345	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—MET—bone cancer	0.000268	0.00345	CbGpPWpGaD
Amsacrine—Vision blurred—Doxorubicin—bone cancer	0.000267	0.00123	CcSEcCtD
Amsacrine—Convulsion—Epirubicin—bone cancer	0.000265	0.00122	CcSEcCtD
Amsacrine—Infection—Methotrexate—bone cancer	0.000265	0.00122	CcSEcCtD
Amsacrine—Anaemia—Doxorubicin—bone cancer	0.000262	0.00121	CcSEcCtD
Amsacrine—Thrombocytopenia—Methotrexate—bone cancer	0.000261	0.00121	CcSEcCtD
Amsacrine—Skin disorder—Methotrexate—bone cancer	0.000259	0.0012	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000259	0.0012	CcSEcCtD
Amsacrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000258	0.00331	CbGpPWpGaD
Amsacrine—Anorexia—Methotrexate—bone cancer	0.000254	0.00118	CcSEcCtD
Amsacrine—Leukopenia—Doxorubicin—bone cancer	0.000253	0.00117	CcSEcCtD
Amsacrine—Confusional state—Epirubicin—bone cancer	0.000252	0.00116	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000252	0.00323	CbGpPWpGaD
Amsacrine—Hypotension—Methotrexate—bone cancer	0.000249	0.00115	CcSEcCtD
Amsacrine—Infection—Epirubicin—bone cancer	0.000248	0.00115	CcSEcCtD
Amsacrine—Convulsion—Doxorubicin—bone cancer	0.000245	0.00113	CcSEcCtD
Amsacrine—Thrombocytopenia—Epirubicin—bone cancer	0.000245	0.00113	CcSEcCtD
Amsacrine—Tachycardia—Epirubicin—bone cancer	0.000244	0.00113	CcSEcCtD
Amsacrine—Skin disorder—Epirubicin—bone cancer	0.000243	0.00112	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—CDK4—bone cancer	0.000242	0.0031	CbGpPWpGaD
Amsacrine—Paraesthesia—Methotrexate—bone cancer	0.00024	0.00111	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000239	0.00111	CcSEcCtD
Amsacrine—Anorexia—Epirubicin—bone cancer	0.000238	0.0011	CcSEcCtD
Amsacrine—Dyspnoea—Methotrexate—bone cancer	0.000238	0.0011	CcSEcCtD
Amsacrine—Hypotension—Epirubicin—bone cancer	0.000233	0.00108	CcSEcCtD
Amsacrine—Confusional state—Doxorubicin—bone cancer	0.000233	0.00108	CcSEcCtD
Amsacrine—Decreased appetite—Methotrexate—bone cancer	0.000232	0.00107	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—DHFR—bone cancer	0.000232	0.00298	CbGpPWpGaD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000232	0.00298	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00023	0.00106	CcSEcCtD
Amsacrine—Fatigue—Methotrexate—bone cancer	0.00023	0.00106	CcSEcCtD
Amsacrine—Infection—Doxorubicin—bone cancer	0.00023	0.00106	CcSEcCtD
Amsacrine—Pain—Methotrexate—bone cancer	0.000228	0.00105	CcSEcCtD
Amsacrine—Thrombocytopenia—Doxorubicin—bone cancer	0.000226	0.00105	CcSEcCtD
Amsacrine—Tachycardia—Doxorubicin—bone cancer	0.000226	0.00104	CcSEcCtD
Amsacrine—Skin disorder—Doxorubicin—bone cancer	0.000224	0.00104	CcSEcCtD
Amsacrine—Paraesthesia—Epirubicin—bone cancer	0.000224	0.00104	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—MMP2—bone cancer	0.000224	0.00288	CbGpPWpGaD
Amsacrine—Dyspnoea—Epirubicin—bone cancer	0.000223	0.00103	CcSEcCtD
Amsacrine—Anorexia—Doxorubicin—bone cancer	0.00022	0.00102	CcSEcCtD
Amsacrine—Feeling abnormal—Methotrexate—bone cancer	0.00022	0.00102	CcSEcCtD
Amsacrine—NCOA3—Metabolism—ENO2—bone cancer	0.000219	0.00281	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Methotrexate—bone cancer	0.000218	0.00101	CcSEcCtD
Amsacrine—Decreased appetite—Epirubicin—bone cancer	0.000217	0.001	CcSEcCtD
Amsacrine—Hypotension—Doxorubicin—bone cancer	0.000216	0.000998	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000216	0.000996	CcSEcCtD
Amsacrine—Fatigue—Epirubicin—bone cancer	0.000215	0.000995	CcSEcCtD
Amsacrine—Pain—Epirubicin—bone cancer	0.000214	0.000987	CcSEcCtD
Amsacrine—Urticaria—Methotrexate—bone cancer	0.000212	0.000979	CcSEcCtD
Amsacrine—Abdominal pain—Methotrexate—bone cancer	0.000211	0.000975	CcSEcCtD
Amsacrine—Body temperature increased—Methotrexate—bone cancer	0.000211	0.000975	CcSEcCtD
Amsacrine—Paraesthesia—Doxorubicin—bone cancer	0.000208	0.000959	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—DHFR—bone cancer	0.000207	0.00266	CbGpPWpGaD
Amsacrine—Dyspnoea—Doxorubicin—bone cancer	0.000206	0.000952	CcSEcCtD
Amsacrine—Feeling abnormal—Epirubicin—bone cancer	0.000206	0.000951	CcSEcCtD
Amsacrine—Gastrointestinal pain—Epirubicin—bone cancer	0.000204	0.000943	CcSEcCtD
Amsacrine—NCOA3—Metabolism—DHFR—bone cancer	0.000203	0.00261	CbGpPWpGaD
Amsacrine—Decreased appetite—Doxorubicin—bone cancer	0.000201	0.000928	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000201	0.00258	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.0002	0.000922	CcSEcCtD
Amsacrine—Fatigue—Doxorubicin—bone cancer	0.000199	0.00092	CcSEcCtD
Amsacrine—Urticaria—Epirubicin—bone cancer	0.000198	0.000917	CcSEcCtD
Amsacrine—Pain—Doxorubicin—bone cancer	0.000198	0.000913	CcSEcCtD
Amsacrine—Body temperature increased—Epirubicin—bone cancer	0.000197	0.000912	CcSEcCtD
Amsacrine—Abdominal pain—Epirubicin—bone cancer	0.000197	0.000912	CcSEcCtD
Amsacrine—Hypersensitivity—Methotrexate—bone cancer	0.000197	0.000908	CcSEcCtD
Amsacrine—Asthenia—Methotrexate—bone cancer	0.000192	0.000885	CcSEcCtD
Amsacrine—Feeling abnormal—Doxorubicin—bone cancer	0.00019	0.00088	CcSEcCtD
Amsacrine—NCOA3—Metabolism—GNA11—bone cancer	0.00019	0.00244	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00019	0.00244	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000189	0.000873	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000187	0.0024	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000184	0.00237	CbGpPWpGaD
Amsacrine—Hypersensitivity—Epirubicin—bone cancer	0.000184	0.00085	CcSEcCtD
Amsacrine—Urticaria—Doxorubicin—bone cancer	0.000184	0.000848	CcSEcCtD
Amsacrine—Abdominal pain—Doxorubicin—bone cancer	0.000183	0.000844	CcSEcCtD
Amsacrine—Body temperature increased—Doxorubicin—bone cancer	0.000183	0.000844	CcSEcCtD
Amsacrine—Diarrhoea—Methotrexate—bone cancer	0.000183	0.000844	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.00018	0.00231	CbGpPWpGaD
Amsacrine—Asthenia—Epirubicin—bone cancer	0.000179	0.000828	CcSEcCtD
Amsacrine—Dizziness—Methotrexate—bone cancer	0.000177	0.000815	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—CHEK2—bone cancer	0.000173	0.00223	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CYP3A4—bone cancer	0.000172	0.00221	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000171	0.0022	CbGpPWpGaD
Amsacrine—Diarrhoea—Epirubicin—bone cancer	0.000171	0.000789	CcSEcCtD
Amsacrine—Hypersensitivity—Doxorubicin—bone cancer	0.00017	0.000786	CcSEcCtD
Amsacrine—Vomiting—Methotrexate—bone cancer	0.00017	0.000784	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—MMP9—bone cancer	0.000168	0.00216	CbGpPWpGaD
Amsacrine—Rash—Methotrexate—bone cancer	0.000168	0.000777	CcSEcCtD
Amsacrine—Dermatitis—Methotrexate—bone cancer	0.000168	0.000777	CcSEcCtD
Amsacrine—Headache—Methotrexate—bone cancer	0.000167	0.000772	CcSEcCtD
Amsacrine—Asthenia—Doxorubicin—bone cancer	0.000166	0.000766	CcSEcCtD
Amsacrine—Dizziness—Epirubicin—bone cancer	0.000165	0.000763	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000162	0.00208	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000161	0.00207	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—BRAF—bone cancer	0.000159	0.00204	CbGpPWpGaD
Amsacrine—Vomiting—Epirubicin—bone cancer	0.000159	0.000734	CcSEcCtD
Amsacrine—Nausea—Methotrexate—bone cancer	0.000159	0.000732	CcSEcCtD
Amsacrine—Diarrhoea—Doxorubicin—bone cancer	0.000158	0.00073	CcSEcCtD
Amsacrine—Rash—Epirubicin—bone cancer	0.000157	0.000727	CcSEcCtD
Amsacrine—Dermatitis—Epirubicin—bone cancer	0.000157	0.000727	CcSEcCtD
Amsacrine—Headache—Epirubicin—bone cancer	0.000156	0.000723	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—JUN—bone cancer	0.000156	0.002	CbGpPWpGaD
Amsacrine—Dizziness—Doxorubicin—bone cancer	0.000153	0.000706	CcSEcCtD
Amsacrine—Nausea—Epirubicin—bone cancer	0.000148	0.000685	CcSEcCtD
Amsacrine—NCOA3—Metabolism—GSTP1—bone cancer	0.000147	0.00189	CbGpPWpGaD
Amsacrine—Vomiting—Doxorubicin—bone cancer	0.000147	0.000679	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—BRCA2—bone cancer	0.000147	0.00189	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000147	0.00189	CbGpPWpGaD
Amsacrine—Rash—Doxorubicin—bone cancer	0.000146	0.000673	CcSEcCtD
Amsacrine—Dermatitis—Doxorubicin—bone cancer	0.000146	0.000672	CcSEcCtD
Amsacrine—Headache—Doxorubicin—bone cancer	0.000145	0.000669	CcSEcCtD
Amsacrine—Nausea—Doxorubicin—bone cancer	0.000137	0.000634	CcSEcCtD
Amsacrine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000137	0.00176	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—EGFR—bone cancer	0.000136	0.00175	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000135	0.00174	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000134	0.00172	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—MDM2—bone cancer	0.000133	0.00171	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000132	0.00169	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000128	0.00164	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000125	0.00161	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDK4—bone cancer	0.000122	0.00157	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000117	0.00151	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000116	0.00148	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000112	0.00144	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000111	0.00143	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDK4—bone cancer	0.000109	0.0014	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000107	0.00138	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—RB1—bone cancer	0.000106	0.00136	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—bone cancer	0.000103	0.00132	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.62e-05	0.00124	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—RB1—bone cancer	9.47e-05	0.00122	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NDUFA12—bone cancer	8.72e-05	0.00112	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.29e-05	0.00106	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NDUFA12—bone cancer	8.21e-05	0.00105	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MDM2—bone cancer	8.08e-05	0.00104	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTGS2—bone cancer	7.63e-05	0.00098	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NT5C3A—bone cancer	7.22e-05	0.000928	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NT5C3A—bone cancer	6.81e-05	0.000874	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.15e-05	0.000789	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.92e-05	0.000761	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.34e-05	0.000686	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—bone cancer	4.64e-05	0.000595	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.2e-05	0.000539	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.53e-05	0.000453	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—ENO2—bone cancer	3.16e-05	0.000406	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—ENO2—bone cancer	2.98e-05	0.000383	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—DHFR—bone cancer	2.93e-05	0.000377	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—DHFR—bone cancer	2.77e-05	0.000355	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GNA11—bone cancer	2.74e-05	0.000352	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GNA11—bone cancer	2.58e-05	0.000332	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYP3A4—bone cancer	2.49e-05	0.000319	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYP3A4—bone cancer	2.34e-05	0.000301	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTP1—bone cancer	2.13e-05	0.000273	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTP1—bone cancer	2e-05	0.000257	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTGS2—bone cancer	1.1e-05	0.000142	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTGS2—bone cancer	1.04e-05	0.000133	CbGpPWpGaD
